The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
J Hsieh, C Longuet, CL Baker, B Qin, LM Federico… - Diabetologia, 2010 - Springer
Aims/hypothesis Glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) agonists and dipeptidyl
peptidase-4 (DPP-4) inhibitors attenuate postprandial lipaemia through mechanisms that …
peptidase-4 (DPP-4) inhibitors attenuate postprandial lipaemia through mechanisms that …
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with …
Aim: The aim of this study was to compare the efficacy and safety of once‐daily human
glucagon‐like peptide‐1 analogue liraglutide with dipeptidyl peptidase‐4 inhibitor …
glucagon‐like peptide‐1 analogue liraglutide with dipeptidyl peptidase‐4 inhibitor …
[HTML][HTML] Vildagliptin attenuates Huntington's disease through activation of GLP-1 receptor/PI3K/Akt/BDNF pathway in 3-nitropropionic acid rat model
Vildagliptin (Vilda), a dipeptidyl peptidase-4 (DPP-4) inhibitor, has been highlighted as a
promising therapeutic agent for neurodegenerative diseases as Alzheimer's and Parkinson's …
promising therapeutic agent for neurodegenerative diseases as Alzheimer's and Parkinson's …
Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 …
OBJECTIVE The objective of this study was to estimate and explain the gap between clinical
efficacy and real-world (RW) effectiveness of type 2 diabetes medications. RESEARCH …
efficacy and real-world (RW) effectiveness of type 2 diabetes medications. RESEARCH …
DPP-4 inhibitors
B Ahren - Best Practice & Research Clinical Endocrinology & …, 2007 - Elsevier
Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4
inhibition prevents the inactivation of glucagon-like peptide 1 (GLP-1), which increases …
inhibition prevents the inactivation of glucagon-like peptide 1 (GLP-1), which increases …
Medications that cause weight gain and alternatives in Canada: a narrative review
S Wharton, L Raiber, KJ Serodio, J Lee… - … syndrome and obesity …, 2018 - Taylor & Francis
Background The cause of the obesity epidemic is multifactorial, but may, in part, be related
to medication-induced weight gain. While clinicians may strive to do their best to select …
to medication-induced weight gain. While clinicians may strive to do their best to select …
Sitagliptin: a review in type 2 diabetes
LJ Scott - Drugs, 2017 - Springer
The dipeptidyl peptidase-4 inhibitor sitagliptin (Januvia®; Glactiv®; Tesavel®; Xelevia™) is
approved in more than 130 countries worldwide as monotherapy and in combination with …
approved in more than 130 countries worldwide as monotherapy and in combination with …
[HTML][HTML] Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management
We congratulate the KDIGO (Kidney Disease: Improving Global Outcomes) work group on
their comprehensive work in a broad subject area and agreed with many of the …
their comprehensive work in a broad subject area and agreed with many of the …
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials
AJ Scheen - Diabetes & metabolism, 2012 - Elsevier
Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2
diabetes. Direct comparisons with active glucose-lowering comparators in drug-naive …
diabetes. Direct comparisons with active glucose-lowering comparators in drug-naive …
Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis
Introduction When first line therapy with metformin is insufficient for patients with type 2
diabetes (T2D), the optimal adjunctive therapy is unclear. We assessed the efficacy and …
diabetes (T2D), the optimal adjunctive therapy is unclear. We assessed the efficacy and …